Study identifies risk potential for thousands of mutations of a cancer gene
Scientists have characterized the role of thousands of mutations in the BRCA2 cancer gene, findings that may help reassure ...
FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo (Dec. 27)
By Sneha S K and Sriparna Roy (Reuters) -The U.S. Food and Drug Administration said on Friday that it has approved an ...
FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo
By Sneha S K and Sriparna Roy (Reuters) - The U.S. Food and Drug Administration said on Friday that it has approved an ...
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors despite daily gains
This was the stock's second consecutive day of gains.
Truist Financial Remains a Buy on Bristol-Myers Squibb (BMY)
In a report released yesterday, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Bristol-Myers Squibb (BMY – Research ...
Bristol Myers price target raised to $65 from $62 at Truist
Truist raised the firm’s price target on Bristol Myers (BMY) to $65 from $62 and keeps a Buy rating on the shares as part of a broader research ...
The T1D Fund Appoints Industry Veteran Elizabeth Mily as CEO to Accelerate Development of Type 1 Diabetes Cures Through Impact Investing
The T1D Fund, an impact investment fund with a focus on accelerating life-changing solutions to treat, prevent, and cure type ...
PharmiWeb3h
Cambridge Cognition highlights positive CANTAB® results in research by Bristol Myers Squib
Cambridge Cognition Holdings plc (AIM: COG), the brain health software group, congratulates Bristol Myers Squibb, the global biopharmaceutical company, for its recent FDA approval of Cobenfy (KarXT™ ...
Cambridge Cognition product used in schizophrenia treatment trial
Cambridge Cognition announced the use of its ‘CANTAB’ cognitive assessment product in two phase three clinical trials conducted by Bristol Myers Squibb for ‘Cobenfy’, a newly FDA-approved treatment ...
BioSpace8h
Pharmas Turn to Licensing Deals as Risky Science Rises
Licensing deals have risen in prominence in a restrained market environment. Is it desperation, or an important part of the ...
manilatimes1h
Aer Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Fexlamose in Chronic Obstructive Pulmonary Disease
Fexlamose is being developed as a chronic treatment for COPD and asthma in conjunction with standard therapies, to improve ...
MPM BioImpact Appoints Brian Shuster, Experienced in Healthcare Corporate Development, as Entrepreneur Partner
MPM BioImpact, a biotechnology investment firm creating and investing in innovative companies seeking to deliver ...